The optimal combination therapy for the treatment of early rheumatoid arthritis

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 11, 2015, Pages 1615-1625

  De Cock, Diederik ^a   Van Der Elst, Kristien ^b   Meyfroidt, Sabrina ^a   Verschueren, Patrick ^b   Westhovens, René ^b  

^a SKELETAL BIOLOGY AND ENGINEERING RESEARCH CENTER   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Biological; Combination treatment; Glucocorticoids; Methotrexate; Patient perspective; Rheumatoid arthritis; Treat to target; Window of opportunity

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; METHOTREXATE; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT;

DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EARLY INTERVENTION; HUMAN; MONOTHERAPY; PHARMACEUTICAL CARE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; THERAPY; THERAPY DELAY; ARTHRITIS, RHEUMATOID; DRUG COMBINATION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS;

EID: 84936934212     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1056735     Document Type: Review

References (105)

1. Scott DL, Smith C, Kingsley G. What are the consequences of early rheumatoid arthritis for the individual? Best Pract Res Clin Rheumatol 2005;19(1):117-36
2. Verstappen S, Jacobs J, Van der Heijde D, et al. Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis. Ann Rheum Dis 2007;66(6):727-31
3. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009;373(9664):659-72
4. Verschueren P, Westhovens R. Optimal care for early RA patients: the challenge of translating scientific data into clinical practice. Rheumatology (Oxford) 2011;50(7):1194-200
5. Hart FD. History of the treatment of rheumatoid arthritis. BMJ 1976;1(6012):763-5
6. Weisman MH. Natural history and treatment decisions in rheumatoid arthritis revisited. Arthritis Care Res 1989;2(3):S75-83
7. Nam JL, Ramiro S, Gaujoux-Viala C, et al. Efficacy of biological diseasemodifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2014;73(3):516-28
8. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364(9430):263-9
9. Korpela M, Laasonen L, Hannonen P, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FINRACo study. Arthritis Rheum 2004;50(7):2072-81
10. Verstappen S, Jacobs J, Van der Veen M, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66(11):1443-9
11. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of Treatment Strategies in Early Rheumatoid ArthritisA Randomized Trial. Ann Intern Med 2007;146(6):406-15
12. Combe B, Benessiano J, Berenbaum F, et al. The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients. Joint bone spine 2007;74(5):440-5
13. Soubrier M, Lukas C, Sibilia J, et al. Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Ann Rheum Dis 2011;70(4):611-15
14. Deighton C, O'Mahony R, Tosh J, et al. Management of rheumatoid arthritis: summary of NICE guidance. BMJ 2009;338:b702
15. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of diseasemodifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64(5):625-39
16. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73(3):492-509
17. Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001;111(6):446-51
18. Raza K, Buckley CE, Salmon M, Buckley CD. Treating very early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2006;20(5):849-63
19. Raza K. The Michael Mason prize: early rheumatoid arthritis-the window narrows. Rheumatology (Oxford) 2010;49(3):406-10
20. van der Linden MP, le Cessie S, Raza K, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum 2010;62(12):3537-46
21. Bosello S, Fedele AL, Peluso G, et al. Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression. Ann Rheum Dis 2011;70(7):1292-5
22. Chan KW, Felson DT, Yood RA, Walker AM. The lag time between onset of symptoms and diagnosis of rheumatoid arthritis. Arthritis Rheum 1994;37(6):814-20
23. Irvine S, Munro R, Porter D. Early referral, diagnosis, and treatment of rheumatoid arthritis: evidence for changing medical practice. Ann Rheum Dis 1999;58(8):510-13
24. Hernandez-Garcia C, Vargas E, Abasolo L, et al. Lag time between onset of symptoms and access to rheumatology care and DMARD therapy in a cohort of patients with rheumatoid arthritis. J Rheumatol 2000;27(10):2323-8
25. Lard LR, Huizinga TW, Hazes JM, Vliet Vlieland TP. Delayed referral of female patients with rheumatoid arthritis. J Rheumatol 2001;28(10):2190-2
26. Mottonen T, Hannonen P, Korpela M, et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002;46(4):894-8
27. Palm O, Purinszky E. Women with early rheumatoid arthritis are referred later than men. Ann Rheum Dis 2005;64(8):1227-8
28. Suter LG, Fraenkel L, Holmboe ES. What factors account for referral delays for patients with suspected rheumatoid arthritis? Arthritis Rheum 2006;55(2):300-5
29. Kumar K, Daley E, Carruthers DM, et al. Delay in presentation to primary care physicians is the main reason why patients with rheumatoid arthritis are seen late by rheumatologists. Rheumatology (Oxford) 2007;46(9):1438-40
30. Feldman DE, Bernatsky S, Haggerty J, et al. Delay in consultation with specialists for persons with suspected new-onset rheumatoid arthritis: a population-based study. Arthritis Rheum 2007;57(8):1419-25
31. Raza K, Stack R, Kumar K, et al. Delays in assessment of patients with rheumatoid arthritis: variations across Europe. Ann Rheum Dis 2011;70(10):1822-5
32. Nanji JA, Choi M, Ferrari R, et al. Time to consultation and disease-modifying antirheumatic drug treatment of patients with rheumatoid arthritis-Northern Alberta perspective. J Rheumatol 2012;39(4):707-11
33. De Cock D, Meyfroidt S, Joly J, et al. A detailed analysis of treatment delay from the onset of symptoms in early rheumatoid arthritis patients. Scand J Rheumatol 2014;43(1):1-8
34. Raza K, Gerlag DM. Preclinical inflammatory rheumatic diseases: an overview and relevant nomenclature. Rheum Dis Clin North Am 2014;40(4):569-80
35. van Dongen H, van Aken J, Lard LR, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007;56(5):1424-32
36. Kay J, Westhovens R. Methotrexate: the gold standard without standardisation. Ann Rheum Dis 2009;68(7):1081-2
37. Dougados M, Combe B, Cantagrel A, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999;58(4):220-5
38. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 1995;333(3):137-41
39. O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334(20):1287-91
40. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995;333(3):142-6
41. Criswell LA, Saag KG, Sems KM, et al. Moderate-term, low-dose corticosteroids for rheumatoid arthritis. Cochrane Database Syst Rev 2000(2):CD001158
42. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350(9074):309-18
43. Calguneri M, Pay S, Caliskaner Z, et al. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. Clin Exp Rheumatol 1999;17(6):699-704
44. Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353(9164):1568-73
45. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007;146(6):406-15
46. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364(9430):263-9
47. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66(11):1443-9
48. Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004;63(9):1062-8
49. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54(1):26-37
50. Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009;68(12):1870-7
51. Kremer J, Ritchlin C, Mendelsohn A, et al. Golimumab, a new human antitumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum 2010;62(4):917-28
52. Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011;70(1):39-46
53. Moreland LW, O'Dell JR, Paulus HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 2012;64(9):2824-35
54. Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 2013;72(6):844-50
55. Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72(1):64-71
56. Dougados M, Kissel K, Conaghan PG, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis 2014;73(5):803-9
57. Nam JL, Villeneuve E, Hensor EM, et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis 2014;73(1):75-85
58. Smolen JS, Emery P, Ferraccioli GF, et al. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. Ann Rheum Dis 2015;74(5):843-50
59. Svensson B, Boonen A, Albertsson K, et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 2005;52(11):3360-70
60. Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 2012;156(5):329-39
61. Heimans L, Wevers-de Boer KV, Visser K, et al. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann Rheum Dis 2014;73(7):1356-61
62. den Uyl D, ter Wee M, Boers M, et al. A non-inferiority trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: clinical results after 26 weeks. Ann Rheum Dis 2014;73(6):1071-8
63. Meyfroidt S, van Hulst L, De Cock D, et al. Factors influencing the prescription of intensive combination treatment strategies for early rheumatoid arthritis. Scand J Rheumatol 2014;43(4):265-72
64. Van der Goes M, Jacobs J, Boers M, et al. Monitoring adverse events of lowdose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 2010;69(11):1913-19
65. Duru N, van der Goes MC, Jacobs JW, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013;72(12):1905-13
66. Leirisalo-Repo M, Kautiainen H, Laasonen L, et al. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebocontrolled study (the NEO-RACo Study). Ann Rheum Dis 2013;72(6):851-7
67. Horslev-Petersen K, Hetland ML, Junker P, et al. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigatorinitiated, randomised, double-blind, parallel-group, placebo-controlled trial. Ann Rheum Dis 2014;73(4):654-61
68. Verschueren P, Esselens G, Westhovens R. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. Rheumatology (Oxford) 2008;47(1):59-64
69. Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 2014;73(1):198-206
70. van Nies JA, Tsonaka R, Gaujoux-Viala C, et al. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden Early Arthritis Clinic and ESPOIR cohorts. Ann Rheum Dis 2015;74(5):806-12
71. Raza K, Filer A. The therapeutic window of opportunity in rheumatoid arthritis: does it ever close? Ann Rheum Dis 2015;74(5):793-4
72. van Vollenhoven RF, Ernestam S, Geborek P, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009;374(9688):459-66
73. O'Dell JR, Curtis JR, Mikuls TR, et al. Validation of the methotrexate-first strategy in patients with early, poorprognosis rheumatoid arthritis: results from a two-year randomized, doubleblind trial. Arthritis Rheum 2013;65(8):1985-94
74. Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 2007;56(10):3226-35
75. Verschueren P, Esselens G, Westhovens R. Predictors of remission, normalized physical function, and changes in the working situation during follow-up of patients with early rheumatoid arthritis: an observational study. Scand J Rheumatol 2009;38(3):166-72
76. Verstappen SM, Jacobs JW, Bijlsma JW, et al. Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year. Arthritis Rheum 2003;48(7):1797-807
77. Ter Wee MM, den Uyl D, Boers M, et al. Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial. Ann Rheum Dis 2015;74(6):1233-40
78. de Jong PH, Hazes JM, Barendregt PJ, et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis 2013;72(1):72-8
79. de Jong PH, Hazes JM, Han HK, et al. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with lowdose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann Rheum Dis 2014;73(7):1331-9
80. Osiri M, Shea B, Welch V, et al. Leflunomide for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd; Hoboken, New Jersey: 2002
81. Verschueren P, De Cock D, Corluy L, et al. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis 2015;74(1):27-34
82. De Cock D, Westhovens R, Corluy L, et al. Comparison of MTX therapy with or without a moderate dose glucocorticoid bridging scheme in early Rheumatoid Arthritis patients lacking classical poor prognostic markers: week 16 results from the randomized multicenter CareRa trial. Ann Rheum Dis 2014;73(Suppl2):220
83. Verschueren P, De Cock D, Corluy L, et al. Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early Rheumatoid Arthritis: week 16 results from the randomized multicenter CareRA trial. Arthritis Res Ther 2015;17(1):97
84. Ajeganova S, Huizinga TWJ. Seronegative and seropositive RA: alike but different? Nat Rev Rheumatol 2015;11(1):9-10
85. De Cock D, Vanderschueren G, Meyfroidt S, et al. The performance of matrices in daily clinical practice to predict rapid radiologic progression in patients with early RA. Semin Arthritis Rheum 2013;43(5):627-31
86. Goekoop-Ruiterman YP, Huizinga TW. Rheumatoid arthritis: can we achieve true drug-free remission in patients with RA? Nat Rev Rheumatol 2010;6(2):68-70
87. van der Woude D, Visser K, Klarenbeek NB, et al. Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies. Rheumatology (Oxford) 2012;51(6):1120-8
88. Hirata S, Saito K, Kubo S, et al. Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study. Arthritis Res Ther 2013;15(5):R135
89. Scott IC, Kingsley GH, Scott DL. Can we discontinue synthetic diseasemodifying anti-rheumatic drugs in rheumatoid arthritis? Clin Exp Rheumatol 2013;31(4 Suppl 78):S4-8
90. Emery P, Hammoudeh M, FitzGerald O, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med 2014;371(19):1781-92
91. van Herwaarden N, den Broeder AA, Jacobs W, et al. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev 2014;9:CD010455
92. Nishimoto N, Amano K, Hirabayashi Y, et al. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol 2014;24(1):17-25
93. van Ingen IL, Lamers-Karnebeek F, Jansen TL. Optimizing the expediency of TNFi in rheumatoid arthritis: offering a TNFi holiday in patients having reached low-disease activity in the maintenance phase. Expert Opin Biol Ther 2014;14(12):1761-7
94. van Vollenhoven RF, Nagy G, Tak PP. Early start and stop of biologics: has the time come? BMC Med 2014;12:25
95. Huizinga TW, Conaghan PG, Martin-Mola E, et al. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis 2015;74(1):35-43
96. Emery P, Burmester GR, Bykerk VP, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis 2015;74(1):19-26
97. Westhovens R, Robles M, Ximenes AC, et al. Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis. Ann Rheum Dis 2015;74(3):564-8
98. Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014;370(25):2377-86
99. van Tuyl LH, Plass AM, Lems WF, et al. Discordant perspectives of rheumatologists and patients on COBRA combination therapy in rheumatoid arthritis. Rheumatology (Oxford) 2008;47(10):1571-6
100. Sanderson T, Morris M, Calnan M, et al. 'It's this whole picture, this wellbeing': patients' understanding of 'feeling well' with rheumatoid arthritis. Chronic Illn 2010;6(3):228-40
101. van Tuyl LH, Hewlett S, Sadlonova M, et al. The patient perspective on remission in rheumatoid arthritis: 'You've got limits, but you're back to being you again'. Ann Rheum Dis 2015;74(6):1004-10
102. Van der Elst K, Meyfroidt S, De Groef A, et al. Unravelling Preferred Outcomes of Disease and Treatment in Patients with Early Rheumatoid Arthritis: a Longitudinal Qualitative Interview Study. Ann Rheum Dis 2014;73(Suppl 2):112
103. van Tuyl LH, Plass AM, Lems WF, et al. Why are Dutch rheumatologists reluctant to use the COBRA treatment strategy in early rheumatoid arthritis? Ann Rheum Dis 2007;66(7):974-6
104. Meyfroidt S, Van der Elst K, De Cock D, et al. Patient experiences with intensive combination-treatment strategies with glucocorticoids for early rheumatoid arthritis. Patient Educ Couns 2015;98(3):384-90
105. Meyfroidt S, Hulscher M, De Cock D, et al. A maximum difference scaling survey of barriers to intensive combination treatment strategies with glucocorticoids in early rheumatoid arthritis. Clin Rheumatol 2015;34(5):861-9